McAdams Wright Ragen’s Novo Nordisk NVO Stock Holding History

McAdams Wright Ragen’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$13.7M	Sell	576,290 -1,560	-0.3%	-$35.9K	0.77%	35
2014 Q2	$13.3M	Buy	577,850 +9,700	+2%	+$214K	0.75%	39
2014 Q1	$13M	Buy	568,150 +11,960	+2%	+$255K	0.8%	33
2013 Q4	$10.3M	Buy	556,190 +38,780	+7%	+$676K	0.68%	39
2013 Q3	$8.76M	Sell	517,410 -26,000	-5%	-$437K	0.69%	39
2013 Q2	$8.42M	Buy	+543,410	New	+$9.04M	0.67%	38

Other funds holding NVO

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

McAdams Wright Ragen's NVO Position: Q3 2014 in Review

McAdams Wright Ragen reduced its Novo Nordisk (NVO) stake by 0.27% in Q3 2014, selling an estimated $35.9K and leaving 576,290 shares worth $13.7M. The position accounts for 0.77% of the portfolio, ranked #35.

McAdams Wright Ragen first reported a position in NVO in Q2 2013 and has held it in 6 quarters since. 469 funds tracked by Wall St. Rank hold NVO as of Q3 2014.

McAdams Wright Ragen held 576,290 shares of Novo Nordisk worth $13.7M as of Q3 2014.
McAdams Wright Ragen sold 1,560 Novo Nordisk shares in Q3 2014, an estimated $35.9K.
Novo Nordisk made up 0.77% of McAdams Wright Ragen's portfolio in Q3 2014, its #35 holding.
McAdams Wright Ragen first reported a position in Novo Nordisk in Q2 2013 and has held it in 6 quarters since.
469 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2014.

Based on McAdams Wright Ragen's 13F filing for Q3 2014, filed 14 Nov 2014.